Real-world study of use patterns and clinical outcomes for patients with myelodysplastic syndrome initiating oral decitabine and cedazuridine or intravenous/subcutaneous hypomethylating agents
Background: Decitabine and cedazuridine (DEC-C) is the only oral hypomethylating agent (HMA) approved for myelodysplastic syndromes (MDS) in the United States. The other HMAs approved for MDS, decitabine and azacitidine, are administered intravenously (IV) or subcutaneously (SC). Objectives: This st...
Guardat en:
| Autors principals: | , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publishing
2026-02-01
|
| Col·lecció: | Therapeutic Advances in Hematology |
| Accés en línia: | https://doi.org/10.1177/20406207261421326 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|